Not exact matches
The current standard
of care for advanced pancreatic cancer — a combination
of nab -
paclitaxel and gemcitabine — was developed by TGen and the HonorHealth Research Institute, and approved by the U.S. Food and Drug
Administration in 2013.
Oral
administration of mebendazole in mice elicited a strong antitumor effect in a subcutaneous model and reduced lesions in experimentally induced lung metastasis without any toxicity when compared with
paclitaxel - treated mice [9,20].
In addition, chronic oral
administration of gabapentin (from day 24 — day 44) also reversed
paclitaxel - induced mechanical hyperalgesia when administered at 100mg / kg but not 50 mg / kg.
Acute, oral
administration of gabapentin (100 mg / kg) reversed mechanical induced allodynia in
paclitaxel - injected rats tested on day 23 and on day 35.